This evidence suggests that overexpression of MB21D2 could represent a novel therapeutic mechanism to reduce the malignant phenotype of ESCC by inhibiting the Wnt/β-catenin signaling pathway, thus providing a new theoretical foundation and data support for future ESCC treatments. This evidence concerns the gene MB21D2 and esophageal squamous cell carcinoma.